Trial Profile
Optimizing Dosing Regimen of Piperacillin/Tazobactam, Prolonged Infusion vs. Regular Infusion, Every 6 Hours, for Nosocomial Pneumonia in ICU Caused by Susceptible Pathogens With Higher MIC
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Piperacillin/tazobactam (Primary)
- Indications Bacteraemia; Nosocomial pneumonia
- Focus Therapeutic Use
- 16 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as per ClinicalTrials.gov record
- 16 Feb 2016 Planned primary completion date changed from 1 Sep 2015 to 1 Nov 2016 as per ClinicalTrials.gov record
- 20 May 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.